(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 3.16% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Johnson & Johnson's revenue in 2025 is $89,331,000,000.On average, 6 Wall Street analysts forecast JNJ's revenue for 2025 to be $218,885,608,720,641, with the lowest JNJ revenue forecast at $216,550,300,462,850, and the highest JNJ revenue forecast at $219,907,879,480,763. On average, 6 Wall Street analysts forecast JNJ's revenue for 2026 to be $226,334,650,385,515, with the lowest JNJ revenue forecast at $223,260,237,319,661, and the highest JNJ revenue forecast at $229,613,979,088,249.
In 2027, JNJ is forecast to generate $236,495,822,662,625 in revenue, with the lowest revenue forecast at $232,256,882,160,101 and the highest revenue forecast at $241,819,026,403,304.